Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

GALENA BIOPHARMA INC
Mes dernières consult.
Most popular
Report
 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -20,0 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -50,8 M
Net income 2018 -52,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 13,7 M
More Financials
Company
Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs.The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Latest news on GALENA BIOPHARMA INC
11/10 GALENA BIOPHARMA : reports 3Q loss
11/09 GALENA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
11/09 GALENA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financia..
11/09 Galena Biopharma Reports Third Quarter 2017 Financial Results
10/19 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Entry into a Material Defini..
10/18 GALENA BIOPHARMA, INC. : Entry into a Material Definitive Agreement (form 8-K)
10/02 GALENA BIOPHARMA, INC. : Other Events (form 8-K)
10/02 GALENA BIOPHARMA : SELLAS Enters into a Clinical Trial Collaboration and Supply ..
10/02 GALENA BIOPHARMA : Announces Completion of Enrollment in Two NeuVax Clinical Tri..
10/02 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Financial Statements and Exh..
More news
Sector news : Pharmaceuticals - NEC
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2016 Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal..
2016 Galena Biopharma beats by $0.02
2016 Notable earnings after Wednesday?s close
2016 RXI PHARMACEUTICALS : Moving On Promising Scar Treatment
2016 Best And Worst Performing Stocks Of 2016
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 2
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Stephen F. Ghiglieri CEO, CFO & Principal Accounting Officer
Sanford J. Hillsberg Chairman
Bijan Nejadnik Chief Medical Officer & Executive Vice President
Stephen S. Galliker Independent Director
Rudolph Nisi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC14
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550